Description
BCMA is a suitable candidate for CAR-T therapies because it is absent on hematopoietic stem cells but selectively expressed on PCs, and BCMA is almost present in MM cells. Proliferation-inducing ligand (APRIL) is a natural ligand for both BCMA.
Creative Biolabs provides a second-generation CAR vector which is designed using IL-11 peptide/protein as the extracellular domain. The vector is constructed for the engineering of T cells to target Human IL-20Rα